The U.S. government has agreed to purchase 300,000 doses of Eli Lilly’s COVID-19 antibody treatment. It plans to pay $375 million for the vials of the drug.
An additional 650,000 doses could be purchased from the Indianapolis-based pharmaceutical company through June 2021.
Patients who receive the medication distributed by the U.S. government will not have any out-of-pocket costs for the drug, but may have to pay a fee for its administration.
Peer reviewed data published in the New England Journal of Medicine showed the drug may have “potential” in treating mild to moderate COVID-19 patients.
The Food and Drug Administration has yet to approve an emergency use authorization application from Lilly that was submitted earlier this month.
Lilly said it plans to produce up to 1 million doses by the end of the year.